RIPK2 targeting therapy (Atomwise)

N/A

Report date: 2024/11/06 15:33:47
NME

Base Information

Drug NameRIPK2 targeting therapy (Atomwise)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase RIPK2 inhibitors
TargetsSerine/threonine-protein kinase RIPK2
Therapy Area/IndicationsImmune System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAtomwise Inc
China Registration ClassN/A

Develop Information

Active CompaniesAtomwise Inc
Inactive CompaniesN/A
Active IndicationsImmune System Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A